AngioDynamics, Inc.  

(Public, NASDAQ:ANGO)   Watch this stock  
Find more results for ango
14.76
+0.09 (0.61%)
After Hours: 14.76 0.00 (0.00%)
Aug 31, 4:41PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 14.63 - 15.12
52 week 13.13 - 19.80
Open 14.63
Vol / Avg. 196,208.00/137,239.00
Mkt cap 529.13M
P/E     -
Div/yield     -
EPS -0.09
Shares 35.90M
Beta 0.93
Inst. own 97%
Oct 28, 2015
AngioDynamics Inc Annual Shareholders Meeting (Estimated) - 2:00PM EDT - Add to calendar
Oct 7, 2015
Q1 2016 AngioDynamics Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Aug 12, 2015
AngioDynamics Inc at Canaccord Genuity Growth Conference
Jul 16, 2015
Q4 2015 AngioDynamics Inc Earnings Call - Webcast
Jul 16, 2015
Q4 2015 AngioDynamics Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (May '15) 2015
Net profit margin -0.90% -0.92%
Operating margin 1.47% -0.28%
EBITD margin - 15.71%
Return on average assets -0.42% -0.42%
Return on average equity -0.60% -0.60%
Employees 1,300 -
CDP Score - -

Address

14 Plaza Dr
LATHAM, NY 12110-2166
United States - Map
+1-518-7981215 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

AngioDynamics, Inc. is engaged in designing, manufacturing and selling a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company's devices are used in minimally invasive, image-guided procedures. The Company’s product offerings fall within three product groupings: Peripheral Vascular, Vascular Access and Oncology/Surgery. The Company’s Peripheral Vascular products include Fluid Management, Venous, Thrombus Management, Angiographic, as well as other products. Image-guided vascular access, or IGVA, involves the use of advanced imaging equipment to guide the placement of catheters that deliver short-term drug therapies into the central venous system. The Company’s Oncology/Surgery product offerings include Microwave Ablation products, Radiofrequency Ablation (RFA) and NanoKnife product lines.

Officers and directors

Howard W. Donnelly Independent Chairman of the Board
Age: 53
Bio & Compensation  - Reuters
Joseph M. DeVivo President, Chief Executive Officer, Director
Age: 48
Bio & Compensation  - Reuters
Mark T. Frost Chief Financial Officer, Executive Vice President
Age: 52
Bio & Compensation  - Reuters
John J. Soto Executive Vice President, Chief Commercial Officer
Age: 51
Bio & Compensation  - Reuters
Gary Barrett Senior Vice President,Quality and Regulatory Affairs
Age: 47
Bio & Compensation  - Reuters
Ben Davis Senior Vice President, Business Development
Age: 51
Bio & Compensation  - Reuters
Barbara Kucharczyk Senior Vice President-Global Operations
Age: 42
Bio & Compensation  - Reuters
Mark A. Stephens Senior Vice President - Administration
Age: 47
Bio & Compensation  - Reuters
Stephen A. Trowbridge Senior Vice President, General Counsel
Age: 41
Bio & Compensation  - Reuters
David F. Burgstahler Independent Director
Age: 47
Bio & Compensation  - Reuters